Pituitary Gland “The Master Gland”
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
GH/IGF-1 Abnormalities and Muscle Impairment: from Basic Research to Clinical Practice
International Journal of Molecular Sciences Review GH/IGF-1 Abnormalities and Muscle Impairment: From Basic Research to Clinical Practice Betina Biagetti * and Rafael Simó * Diabetes and Metabolism Research Unit, Vall d’Hebron Research Institute and CIBERDEM (ISCIII), Universidad Autónoma de Barcelona, 08193 Bellaterra, Spain * Correspondence: [email protected] (B.B.); [email protected] (R.S.); Tel.: +34-934894172 (B.B.); +34-934894172 (R.S.) Abstract: The impairment of skeletal muscle function is one of the most debilitating least understood co-morbidity that accompanies acromegaly (ACRO). Despite being one of the major determinants of these patients’ poor quality of life, there is limited evidence related to the underlying mechanisms and treatment options. Although growth hormone (GH) and insulin-like growth factor-1 (IGF-1) levels are associated, albeit not indisputable, with the presence and severity of ACRO myopathies the precise effects attributed to increased GH or IGF-1 levels are still unclear. Yet, cell lines and animal models can help us bridge these gaps. This review aims to describe the evidence regarding the role of GH and IGF-1 in muscle anabolism, from the basic to the clinical setting with special emphasis on ACRO. We also pinpoint future perspectives and research lines that should be considered for improving our knowledge in the field. Keywords: acromegaly; myopathy; review; growth hormone; IGF-1 1. Introduction Acromegaly (ACRO) is a rare chronic disfiguring and multisystem disease due to Citation: Biagetti, B.; Simó, R. non-suppressible growth hormone (GH) over-secretion, commonly caused by a pituitary GH/IGF-1 Abnormalities and Muscle tumour [1]. -
Joy Wellness Partners 838 W G Street Suite 201 San Diego, California 92101
United States of America FEDERAL TRADE COMMISSION Southwest Region 1999 Bryan St., Ste. 2150 Dallas, Texas 75201 June 3, 2020 WARNING LETTER VIA EMAIL TO [email protected] Joy Wellness Partners 838 W G Street Suite 201 San Diego, California 92101 Re: Unsubstantiated Claims for Coronavirus Prevention or Treatment To Whom It May Concern, This is to advise you that FTC staff reviewed your website at https://joywellnesspartners.com/ on May 24, 2020. We have determined that you are unlawfully advertising that certain products treat or prevent Coronavirus Disease 2019 (COVID-19). Some examples of Coronavirus treatment or prevention claims on your website include: In marketing materials accessible on your website by selecting “BLOG” from the navigation menu and clicking on “CORONAVIRUS (COVID-19),” you claim: o Under the heading “Hormones, Peptides, & Immunity”: . You state that “Keeping your immune system running optimally with balanced hormones and peptides helps your body prevent and fight illness, including viruses like COVID-19. Book now [https://intakeq.com/booking/8hkwjk]” . You post a video titled “IMMUNITY, BIOTE, & CORONAVIRUS” featuring Carol Joy Bender, NP. In the video at approximately 31:55, Bender states, “More specifically, I wanted to touch on the things that we’re all concerned about the coronavirus times: what can I do to boost my immune system to keep me healthy? BioTE has already been doing this for us… We have a lot of patients that are already taking their iodine with selenium and zinc. The zinc is one of the mainstay treatments that many of you have read about… zinc helps to reduce the RNA replication inside the cells, when the coronavirus gets in. -
Endogenous Peptide Discovery of the Rat Circadian Clock a FOCUSED STUDY of the SUPRACHIASMATIC NUCLEUS by ULTRAHIGH PERFORMANCE TANDEM MASS □ SPECTROMETRY* S
Research Endogenous Peptide Discovery of the Rat Circadian Clock A FOCUSED STUDY OF THE SUPRACHIASMATIC NUCLEUS BY ULTRAHIGH PERFORMANCE TANDEM MASS □ SPECTROMETRY* S Ji Eun Lee‡§, Norman Atkins, Jr.¶, Nathan G. Hatcherʈ, Leonid Zamdborg‡§, Martha U. Gillette§¶**, Jonathan V. Sweedler‡§¶ʈ, and Neil L. Kelleher‡§‡‡ Understanding how a small brain region, the suprachias- pyroglutamylation, or acetylation. These aspects of peptide matic nucleus (SCN), can synchronize the body’s circa- synthesis impact the properties of neuropeptides, further ex- dian rhythms is an ongoing research area. This important panding their diverse physiological implications. Therefore, time-keeping system requires a complex suite of peptide unveiling new peptides and unreported peptide properties is hormones and transmitters that remain incompletely critical to advancing our understanding of nervous system characterized. Here, capillary liquid chromatography and function. FTMS have been coupled with tailored software for the Historically, the analysis of neuropeptides was performed analysis of endogenous peptides present in the SCN of the rat brain. After ex vivo processing of brain slices, by Edman degradation in which the N-terminal amino acid is peptide extraction, identification, and characterization sequentially removed. However, analysis by this method is from tandem FTMS data with <5-ppm mass accuracy slow and does not allow for sequencing of the peptides con- produced a hyperconfident list of 102 endogenous pep- taining N-terminal PTMs (5). Immunological techniques, such tides, including 33 previously unidentified peptides, and as radioimmunoassay and immunohistochemistry, are used 12 peptides that were post-translationally modified with for measuring relative peptide levels and spatial localization, amidation, phosphorylation, pyroglutamylation, or acety- but these methods only detect peptide sequences with known lation. -
Thymosin Hh10 Inhibits Angiogenesis and Tumor Growth by Interfering with Ras Function
Research Article Thymosin hh10 Inhibits Angiogenesis and Tumor Growth by Interfering with Ras Function Seung-Hoon Lee,1 Myung Jin Son,1,2 Sun-Hee Oh,1 Seung-Bae Rho,1 Kyungsook Park,1 Yung-Jin Kim,2 Mi-Sun Park,1 and Je-Ho Lee1 1Molecular Therapy Research Center, Samsung Medical Center, School of Medicine, Sung Kyun Kwan University, Seoul, Korea and 2Department of Molecular Biology, Pusan National University, Busan, Korea Abstract are a family of highly conserved small peptides that inhibit barbed end actin polymerization by sequestering actin mono- Thymosin h10 is a monomeric actin sequestering protein mers (8). Among them, thymosin h4 and thymosin h10 are the that regulates actin dynamics. Previously, we and others h have shown that thymosin h acts as an actin-mediated two most abundant -thymosins in the mammalian species and 10 coexist in some tissue types at varying ratios (9). Although both tumor suppressor. In this study, we show that thymosin h10 is not only a cytoskeletal regulator, but that it also acts as a peptides share a high degree of sequence homology, they show potent inhibitor of angiogenesis and tumor growth by its distinct patterns of expression in several tissues (10) and play interaction with Ras. We found that overexpressed thymosin different roles during rodent development (11). Recently, the angiogenic effects of several members of the thymosin family of h10 significantly inhibited vascular endothelial growth factor–induced endothelial cell proliferation, migration, peptides were studied in the chick chorioallantoic membrane h a invasion, and tube formation in vitro. Vessel sprouting was model (12). -
Neuroendocrine Imaging
ACR APPROPRIATENESS CRITERIA Neuroendocrine Imaging D.J. Seidenwurm, for the Expert Panel on Neurologic Imaging maging of the hypothalamic pituitary axis is based on spe- pending on serum hormone level. In males, prolactinomas Icific endocrine testing suggested by clinical signs and symp- may be entirely asymptomatic until visual symptoms occur, toms. Endocrine disorders are generally characterized by ex- due to compression of the chiasm, or they may result in hy- cess or deficiency of specific hormones. Hormone excess is pogonadotropic hypogonadism with loss of libido and impo- diagnosed under conditions that would ordinarily suppress tence. Growth-hormone-secreting tumors generally are larger hormone secretion. Endocrine deficiencies are diagnosed on lesions manifesting clinical acromegaly. Because of the gradual the basis of hormone measurements under conditions of stim- onset of deformity, these tumors may be present for many ulation. Specific clinical syndromes of hormonal disorders are years and grow to substantial size. Before puberty excessive determined by the physiologic role of that particular GH may result in gigantism. TSH- and ACTH-secreting tu- hormone. mors may present at very small size because the impact of their The hypothalamic pituitary axis consists of 2 separate neu- hormone product is usually apparent more rapidly. Gonado- roendocrine organs, the anterior and posterior pituitary sys- tropin-secreting tumors are rare. tems. The hormones of the anterior pituitary are thyroid stim- Precocious puberty and other neurologic symptoms can be ulating hormone (TSH), adrenal corticotrophic hormone produced by hypothalamic lesions such as hamartoma. MR (ACTH), prolactin (PRL), growth hormone (GH), and the imaging is generally indicated in all patients with endocrino- gonadotropins (FSH and LH). -
Multiple Beneficial Effects of Melanocortin MC4 Receptor
View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Archivio della ricerca - Università degli studi di Napoli Federico II Progress in Neurobiology 148 (2017) 40–56 Contents lists available at ScienceDirect Progress in Neurobiology journal homepage: www.elsevier.com/locate/pneurobio Review article Multiple beneficial effects of melanocortin MC4 receptor agonists in experimental neurodegenerative disorders: Therapeutic perspectives a a a b c Daniela Giuliani , Alessandra Ottani , Laura Neri , Davide Zaffe , Paolo Grieco , d e f a, Jerzy Jochem , Gian Maria Cavallini , Anna Catania , Salvatore Guarini * a Department of Biomedical, Metabolic and Neural Sciences, Section of Pharmacology and Molecular Medicine, University of Modena and Reggio Emilia, Modena, Italy b Department of Biomedical, Metabolic and Neural Sciences, Section of Human Morphology, University of Modena and Reggio Emilia, Modena, Italy c Department of Pharmacy, University of Napoli “Federico II”, Napoli, Italy d Department of Basic Medical Sciences, School of Public Health in Bytom, Medical University of Silesia, Katowice, Poland e Department of Ophthalmology, University of Modena and Reggio Emilia, Modena, Italy f Center for Preclinical Surgical Research, Fondazione IRCCS Ca' Granda À Ospedale Maggiore Policlinico, Milano, Italy A R T I C L E I N F O A B S T R A C T Article history: Received 20 May 2015 Melanocortin peptides induce neuroprotection in acute and chronic experimental neurodegenerative Received in revised form 22 November 2016 conditions. Melanocortins likewise counteract systemic responses to brain injuries. Furthermore, they Accepted 28 November 2016 promote neurogenesis by activating critical signaling pathways. Melanocortin-induced long-lasting Available online 1 December 2016 improvement in synaptic activity and neurological performance, including learning and memory, sensory-motor orientation and coordinated limb use, has been consistently observed in experimental Keywords: models of acute and chronic neurodegeneration. -
Supporting Information for Proteomics DOI 10.1002/Pmic.200700142
Supporting Information for Proteomics DOI 10.1002/pmic.200700142 Karl Skld, Marcus Svensson, Mathias Norrman, Benita Sjgren, Per Svenningsson and Per E. Andren´ The significance of biochemical and molecular sample integrity in brain proteomics and peptidomics: Stathmin 2-20 and peptides as sample quality indicators ª 2007 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.proteomics-journal.com SUPPORTING INFORMATION Supporting Information Table 1. Degraded protein identities and peptide sequences in the striatum after 1, 3, and 10 min post-mortem. UniProtKBa. Protein name Sequenceb Scorec P60710/P63260 Actin, cytoplasmic 1,2 A.LVVDNGSGMCK.A 56 E.MATAASSSSLEKS.Y 55 W.IGGSILASLSTFQQ.M 64 W.ISKQEYDESGPSIVHRK.C 93 M.WISKQEYDESGPSIVHRK.C 56 Q8K021 Secretory carrier-associated F.ATGVMSNKTVQTAAANAASTAATSAAQNAFKGNQM.- 124 membrane protein 1 Q9D164 FXYD domain-containing ion L.ITTNAAEPQK.A 58 transport regulator 6 precursor L.ITTNAAEPQKA.E 57 L.ITTNAAEPQKAE.N 89 L.ITTNAAEPQKAEN.- 54 P99029 Peroxiredoxin 5, mitochondrial M.APIKVGDAIPSVEVF.E 57 precursor P01942 Hemoglobin alpha subunit F.LASVSTVLTSKYR.- 106 M.FASFPTTKTYFPHF.D 72 L.ASHHPADFTPAVHASLDK.F 76 T.LASHHPADFTPAVHASLDK.F 59 L.LVTLASHHPADFTPAVHAS.L 56 L.LVTLASHHPADFTPAVHASLDK.F 71 L.LVTLASHHPADFTPAVHASLDKFLASVST.V 66 T.LASHHPADFTPAVHASLDKFLAS.V 55 L.VTLASHHPADFTPAVHASLDKFLAS.V 68 -.VLSGEDKSNIKAAWGKIGGHGAEYGAEALER.M 97 -.VLSGEDKSNIKAAWGKIGGHGAEYGAEALERM.F 58 P02088/P02089 Hemoglobin beta-1,2 subunit L.LVVYPWTQRY.F 53 L.LVVYPWTQRYF.D 52 Q00623 Apolipoprotein A-I precursor Y.VDAVKDSGRDYVSQFESSSLGQQLN.L -
Acromegaly Your Questions Answered Patient Information • Acromegaly
PATIENT INFORMATION ACROMEGALY YOUR QUESTIONS ANSWERED PATIENT INFORMATION • ACROMEGALY Contents What is acromegaly? 1 What does growth hormone do? 1 What causes acromegaly? 2 What is acromegaly? Acromegaly is a rare disease characterized by What are the signs and symptoms of acromegaly? 2 excessive secretion of growth hormone (GH) by a pituitary tumor into the bloodstream. How is acromegaly diagnosed? 5 What does growth hormone do? What are the treatment options for acromegaly? 6 Growth hormone (GH) is responsible for growth and development of the human body especially during childhood and adolescence. In addition, Will I need treatment with any other hormones? 9 GH has important functions during later life. It influences fat and glucose (sugar) metabolism, and muscle and bone strength. Growth hormone is How can I expect to feel after treatment? 9 produced in the pituitary gland which is a small bean-sized organ located just underneath the brain (Figure 1). The pituitary gland also secretes How should patients with acromegaly be followed after initial treatment? 9 other hormones into the bloodstream to regulate important functions including reproduction, energy, breast lactation, water balance control, and metabolism. What do I need to do if I have acromegaly? 10 Acromegaly Frequently Asked Questions (FAQs) 10 Glossary inside back cover Pituitary gland Funding was provided by Ipsen Group, Novo Nordisk, Inc. and Pfizer, Inc. through Figure 1. Location of the pituitary gland. unrestricted educational grants. This is the fourth of the series of informational pamphlets provided by The Pituitary Society. Supported by an unrestricted educational grant from Eli Lilly and Company. -
Information to Users
INFORMATION TO USERS This manuscript has been reproduced from the microfilm master. UMI films the text directly from the original or copy submitted. Thus, some thesis and dissertation copies are in typewriter face, while others may be from any type of computer printer. The quality of this reproduction is dependent upon the quality of the copy submitted. Broken or indistinct print, colored or poor quality illustrations and photographs, print bleedthrough, substandard margins, and improper alignment can adversely affect reproduction. In the unlikely event that the author did not send UMI a complete manuscript and there are missing pages, these will be noted. Also, if unauthorized copyright material had to be removed, a note will indicate the deletion. Oversize materials (e.g., maps, drawings, charts) are reproduced by sectioning the original, beginning at the upper left-hand comer and continuing from left to right in equal sections with small overlaps. Each original is also photographed in one exposure and is included in reduced form at the back of the book. Photographs included in the original manuscript have been reproduced xerographically in this copy. Higher quality 6" x 9" black and white photographic prints are available for any photographs or illustrations appearing in this copy for an additional charge. Contact UMI directly to order. A Bell & Howell Information Company 300 North Zeeb Road. Ann Arbor. Ml 48106-1346 USA 313/761-4700 800/521-0600 Order Number 9517090 Partial characterization and purification of steroidogenic factors in thymic epithelial cell culture-conditioned medium Uzumcu, Mehmet, Ph.D. The Ohio State University, 1994 UMI 300 N. -
Stabilization Stabilizor Workflow Inactivation of Enzymes
Denator Novel Tissue Sample Preparation Technology for MS Analysis denator.com WATERS 2nd NORDIC MS SYMPOSIUM Tuesday Nov 8 2011 Båstad Katarina Alenäs Denator 2004 University spin-off 2006 Head office at Biotech Center Gothenburg, Sweden Research lab in Uppsala Science Park, Sweden 2008 Stabilizor T1 – Launch 2009-to date Publications: Svensson et al. “Heat stabilization of the tissue proteome” Journal of Proteome Research, 2009 Robinson et al. “Assessing the use of thermal treatment to preserve the intact proteomes of post-mortem heart and brain tissue” Proteomics, 2009 Scholz et al. “Impact of temperature dependent sampling procedures in proteomics and peptidomics” Molecular and Cellular Proteomics, 2010 Goodwin et al. “Stopping the clock on proteomic degradation by heat-treatment at the point of tissue excision” Proteomics, 2010 Rountree et al “Clinical application for the preservation of phospho-proteins through in-situ tissue stabilization” Proteome Science, 2010 Ahmed et al “Preserving protein profiles in tissue samples: Differing outcomes with and without heat stabilization” Journal of Neuroscience Methods, 2011 Colgrave et al “Neuropeptide profiling of the bovine hypothalamus: Thermal stabilization is an effective tool in inhibiting post-mortem degradation” Colgrave et al, Proteomics, 2011 Protein research workflow Collection Sample prep Analysis Bioinformatics Stabilization Extraction 2D-gels Dissection Clean up MS Storage Enrichment Western blot Transport Trypsin cleavage ELISA Laboratory for Biological and Medical Mass Spectrometry, -
Acromegaly in a Girl of 8 Years
Arch Dis Child: first published as 10.1136/adc.33.167.49 on 1 February 1958. Downloaded from ACROMEGALY IN A GIRL OF 8 YEARS BY R. McLAREN TODD From the Department of Child Health, University ofLiverpool (RECEIVED FOR PUBLICATION JUNE 21, 1957) Pierre Marie in 1886 first suggested the name of 6 years who lived in Brno (Traub, 1939) and acromegaly for a clinical condition associated with showed acromegalic gigantism associated with bony enlargement of the extremities (aKpa) which he changes in the right hip, tarsal scaphoids, metatarsals had observed in two women aged 37 and 54 years. and vertebral bodies. Marie reviewed the literature and found records of Case Report five male patients (two of whom were brothers) G.O. was born on August 23, 1947, after a normal with similar features; the earliest of these descrip- pregnancy and delivery. She weighed 7j lb. at birth and tions concerned a man of 39 years reported by developed normally until the age of 5 years when she Saucerotte (1772). Marie also discussed the had a mild attack of whooping cough. After this illness differential diagnosis of acromegaly from myx- her mother noticed that she tired easily and that she was oedema, Paget's disease of bone (osteitis deformans) putting on weight excessively. It was not until two years later that the symptoms became more obvious. She and leontiasis ossea of Virchow. consulted her family doctor (Dr. W. Jones Morris) in Although Saucerotte's account is probably the July, 1954, when she was 6 years 11 months old because earliest medical description of acromegaly, the con- of persistent nasal catarrh and he observed the acro- dition was well known to ancient writers. -
Lessons from Growth Hormone Receptor Gene-Disrupted Mice
5 178 R Basu, Y Qian and others Lessons from GHR-disrupted mice 178:5 R155–R181 Review MECHANISMS IN ENDOCRINOLOGY Lessons from growth hormone receptor gene-disrupted mice: are there benefits of endocrine defects? Reetobrata Basu1,*, Yanrong Qian1,* and John J Kopchick1,2 1 2 Edison Biotechnology Institute, Ohio University, Athens, Ohio, USA and Ohio University Heritage College of Correspondence Osteopathic Medicine, Ohio University, Athens, Ohio, USA should be addressed to J J Kopchick *(R Basu and Y Qian contributed equally to this work) Email [email protected] Abstract Growth hormone (GH) is produced primarily by anterior pituitary somatotroph cells. Numerous acute human (h) GH treatment and long-term follow-up studies and extensive use of animal models of GH action have shaped the body of GH research over the past 70 years. Work on the GH receptor (R)-knockout (GHRKO) mice and results of studies on GH-resistant Laron Syndrome (LS) patients have helped define many physiological actions of GH including those dealing with metabolism, obesity, cancer, diabetes, cognition and aging/longevity. In this review, we have discussed several issues dealing with these biological effects of GH and attempt to answer the question of whether decreased GH action may be beneficial. European Journal of Endocrinology European Journal European of Endocrinology (2018) 178, R155–R181 Introduction An extensive body of basic and clinical research over the with distinct catabolic and anabolic roles across many last 70 years focusing on growth hormone (GH) and its tissue types and throughout the lifespan of an individual. cognate receptor (GHR) has yielded a tremendous amount The clinical conditions of GH excess usually due to a of animal and human data.